TherapeuticsMD Inc (TXMD)

The maker of women's health products could receive FDA approval for two late-stage products in the next 18 months.

It was a busy time of earnings reports for the model portfolio, as the market rose for the sixth straight week.

We maintain our Two rating and price target on each stock.

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its second quarter financial results for the quarter ended June 30, 2016.

Ballantyne Strong, Builders FirstSource, Kratos Defense & Security and Therapeutics MD are on tap for after-hours releases.

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss second quarter financial and business results on...

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, announced today that it has submitted its New Drug Application (NDA) for Yuvvexy with the U.

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, announced today that it expects that the New Drug Application (NDA) for Yuvvexy, the conditionally approved trade name for the Company's...

With market weakness expected to continue to linger, our model portfolio considers it a potentially good time to buy.

We trimmed two positions in the model portfolio this week amid overall market strength.

TherapeuticsMD, Inc. (NYSE MKT:TXMD) an innovative women's healthcare company and parent company of vitaMedMD ®, LLC ("vitaMedMD") and BocaGreenMD ®, Inc.

With the probability of an interest rate hike at the June FOMC of just 4% and also lingering uncertainty about rising interest rates over coming weeks and months, we remain comfortable with the model portfolio.

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming investor conferences.

U.S. shares advanced for the week, but we did not make any trades in our model portfolio. Next week, however, a plethora of economic data will be released.

U.S. stocks are approaching oversold levels for the first time in over a month, leaving us comfortable with an above-average 25% cash position in our model portfolio as we search for new names to add.

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, presented additional secondary endpoint results from the pivotal phase 3 Rejoice Trial for its TX-004HR product candidate at the American...

U.S. stocks are approaching oversold levels for the first time in over a month, prompting our model portfolio to increase its position in Kratos Defense & Security.

More than half of the model portfolio reported earnings in a 48-hour stretch, but earnings season wraps up next week amid a quiet economic front.

Earnings disappointed, but the clinical pipeline is reassuring.

Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a weak on high relative volume candidate

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming investor conferences.

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its first quarter financial results for the quarter ended March 31, 2016.

Several names in the model portfolio experienced increased volatility, despite U.S. stocks posting just fractional losses this week and holding near record highs.

With the market ticking higher this week, we used its strength to take profits in some of our portfolio companies.

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss first quarter 2016 financial and business results on...

This week, we used the market rally to book profits in 2 holdings.

We made just one trade for the model portfolio this week as the market ended with a fractional loss.

Biotechs are leading, which tells me there's enough speculative interest.